Pages that link to "Q33966248"

The following pages link to Incidence and impact of resistance against approved antiretroviral drugs (Q33966248):

Displaying 43 items.

• Analysis of HIV-1 drug resistant mutations by line probe assay and direct sequencing in a cohort of therapy naive HIV-1 infected Italian patients (Q24795766) (← links)
• Structure of the Antiviral Assembly Inhibitor CAP-1 Complex with the HIV-1 CA Protein (Q27647971) (← links)
• Small molecule modulators of HIV Rev/Rev response element interaction identified by random screening (Q28204246) (← links)
• A randomised trial of subcutaneous intermittent interleukin-2 without antiretroviral therapy in HIV-infected patients: the UK-Vanguard Study (Q28469017) (← links)
• Effects of intermittent IL-2 alone or with peri-cycle antiretroviral therapy in early HIV infection: the STALWART study (Q33534648) (← links)
• Antiretroviral drug resistance testing in patients with HIV-1 infection: a meta-analysis study (Q34112020) (← links)
• In vivo toxicity, pharmacokinetics, and anti-human immunodeficiency virus activity of stavudine-5'-(p-bromophenyl methoxyalaninyl phosphate) (stampidine) in mice (Q34141998) (← links)
• In vitro antiretroviral activity and in vitro toxicity profile of SPD754, a new deoxycytidine nucleoside reverse transcriptase inhibitor for treatment of human immunodeficiency virus infection (Q34352006) (← links)
• Ongoing trials of immune-based therapies for HIV infection in adults (Q34451967) (← links)
• Molecular techniques should now replace cell culture in diagnostic virology laboratories (Q34464937) (← links)
• Molecular techniques should not now replace cell culture in diagnostic virology laboratories (Q34464943) (← links)
• Mechanistic aspects of HIV-1 reverse transcription initiation (Q34490256) (← links)
• Resistance in viruses other than HIV. (Q34666651) (← links)
• Structure-based design and engineering of a nontoxic recombinant pokeweed antiviral protein with potent anti-human immunodeficiency virus activity (Q34734416) (← links)
• Protein-protein interactions as targets for antiviral chemotherapy (Q34747522) (← links)
• Considerations and development of topical microbicides to inhibit the sexual transmission of HIV. (Q34768558) (← links)
• In vivo antiretroviral activity of stampidine in chronically feline immunodeficiency virus-infected cats (Q34883567) (← links)
• Synthesis and evaluation of 3'-azido-2',3'-dideoxypurine nucleosides as inhibitors of human immunodeficiency virus (Q34952588) (← links)
• HIV mutagenesis and the evolution of antiretroviral drug resistance (Q35046890) (← links)
• The next generation of HIV/AIDS drugs: novel and developmental antiHIV drugs and targets (Q35917148) (← links)
• Immunopathogenesis of oropharyngeal candidiasis in human immunodeficiency virus infection. (Q35920633) (← links)
• Current status of gene therapy strategies to treat HIV/AIDS. (Q36143446) (← links)
• Structural probing of the HIV-1 polypurine tract RNA:DNA hybrid using classic nucleic acid ligands (Q36649670) (← links)
• Enhanced antibody responses elicited by a CpG adjuvant do not improve the protective effect of an aldrithiol-2-inactivated simian immunodeficiency virus therapeutic AIDS vaccine (Q37156717) (← links)
• A recombinant virus assay using full-length envelope sequences to detect changes in HIV-1 co-receptor usage (Q38974088) (← links)
• Combination of drugs and drug-resistant reverse transcriptase results in a multiplicative increase of human immunodeficiency virus type 1 mutant frequencies (Q39684476) (← links)
• Identification of a critical motif for the human immunodeficiency virus type 1 (HIV-1) gp41 core structure: implications for designing novel anti-HIV fusion inhibitors (Q39766027) (← links)
• Adaptive HIV-1 evolutionary trajectories are constrained by protein stability (Q40065675) (← links)
• Immunological cross-reactivity against a drug mutated HIV-1 protease epitope after DNA multi-CTL epitope construct immunization. (Q40369476) (← links)
• Natural variation of drug susceptibility in wild-type human immunodeficiency virus type 1 (Q40469287) (← links)
• Development and automation of a 384-well cell fusion assay to identify inhibitors of CCR5/CD4-mediated HIV virus entry (Q40510097) (← links)
• Demonstration of sustained drug-resistant human immunodeficiency virus type 1 lineages circulating among treatment-naïve individuals (Q43173413) (← links)
• HIV antiviral drug resistance: patient comprehension (Q43690728) (← links)
• Antiretroviral drug resistance among HIV-1 infected children failing treatment. (Q44134172) (← links)
• Multidrug-resistant HIV-1 reverse transcriptase: involvement of ribonucleotide-dependent phosphorolysis in cross-resistance to nucleoside analogue inhibitors. (Q44180443) (← links)
• Antiviral inhibition of the HIV-1 capsid protein (Q44380725) (← links)
• Inhibition of HIV replication: a powerful antiviral strategy by IFN-beta gene delivery in CD4+ cells (Q45869827) (← links)
• Sch 213766, a novel chemokine receptor CCR-5 inhibitor from Chaetomium globosum (Q50916069) (← links)
• Immunological and virological consequences of patient-directed antiretroviral therapy interruption during chronic HIV-1 infection. (Q53653066) (← links)
• Increasing prevalence of resistance mutations in antiretroviral-naïve individuals with established HIV-1 infection from 1996-2001 in St. Louis. (Q53972839) (← links)
• Prevalence of multiple dideoxynucleoside analogue resistance (MddNR) in a cohort of Italian HIV-1 seropositive patients extensively treated with antiretroviral drugs. (Q53986291) (← links)
• Will systemic antivirals be sold over the counter? (Q73656963) (← links)
• DNA immunization in combination with effective antiretroviral drug therapy controls viral rebound and prevents simian AIDS after treatment is discontinued (Q82385263) (← links)